Diarrhoea is one of the most common diseases, globally, affecting children under five years of age. Although typically being a...

ShigETEC is an orally administered vaccine candidate developed by Eveliqure.

Shigella-ETEC combination vaccine for travellers and children in resource poor countries is supported by the Wellcome Trust.

The SHIGETECVAX consortium and Eveliqure included in the “Success Story” series of the Austrian Research Promotion Agency (FFG)

The official kick-off meeting of the SHIGETECVAX project was held at the Eveliqure facilities in Vienna, Austria.

SHIGETECVAX included in the Community Research and Development Information Service (CORDIS).

Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials.